Panel Discussion: From lab to market: Scaling formulation science

Panellists in this video:
Panellists in this video:
• Dr Ravikumar N, President – Formulations R&D, MSN Laboratories (Moderator)
• Dr Pavan Bhat, MD & CEO, Inventia Healthcare
• Dr Vellaian Karuppiah, COO, Shilpa Medicare
• Dr Pankaj Mandpe, EVP-R&D, Micro Labs
• Dr Madhusudhan Bommagani, President, FR&D, Cadila Pharmaceuticals
• Dr Vasanthakumar Ramu, Head R&D (Peptides & Complex Generics), Alembic Pharmaceuticals
• Dr Saurabh Gupta, VP & Delivery Manager- Integrated Product Development, Dr Reddy’s Laboratories
• Dr Ratnakar P Mehendre, Director, Shuban Pharmaceuticals

Key Highlights:
[1] Novel platforms and botanical drugs can create global opportunities for India when supported by strong clinical evidence and regulatory planning.

[2] Strong formulations are built to handle variability and scale-up challenges from the start.

[3] Successful commercialisation depends on transferring practical learnings, not just data and documents.

[4] The focus must shift from cost alone to quality, value and patient benefit.

[5] Technology is no longer just supporting drug development. It is driving innovation, efficiency, and value creation across the entire process.

[6] Early understanding of CPPs and CQAs reduces risk and builds stronger products.

[7] Continuous manufacturing is becoming a competitive advantage. It enables real-time monitoring, lower inventory, improved efficiency, and stronger compliance.

[8] Cross-functional collaboration is essential. Development and process teams should work together from equipment selection through commercialisation.

[9] Product design should consider future demand, scalability, manufacturability, and cost without compromising quality.

The post Panel Discussion: From lab to market: Scaling formulation science appeared first on Express Pharma.